TY - JOUR AU - Miller, M. PY - 2000 DA - 2000// TI - Phase I cancer trials. A collusion of misunderstanding JO - Hastings Cent Rep VL - 30 UR - https://doi.org/10.2307/3527646 DO - 10.2307/3527646 ID - Miller2000 ER - TY - JOUR AU - Rogatko, A. AU - Schoeneck, D. AU - Jonas, W. AU - Tighiouart, M. AU - Khuri, F. R. AU - Porter, A. PY - 2007 DA - 2007// TI - Translation of innovative designs into phase I trials JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.12.1012 DO - 10.1200/JCO.2007.12.1012 ID - Rogatko2007 ER - TY - JOUR AU - Markman, M. PY - 2006 DA - 2006// TI - “Therapeutic intent” in phase 1 oncology trials: a justifiable objective JO - Arch Intern Med VL - 166 UR - https://doi.org/10.1001/archinte.166.14.1446 DO - 10.1001/archinte.166.14.1446 ID - Markman2006 ER - TY - STD TI - “General principles of the IND submission,” Title 21 Code of Federal Regulations, Pt. 312.22. 2011,http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.22, ed, UR - http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.22 ID - ref4 ER - TY - JOUR AU - Hidalgo, M. AU - Siu, L. L. AU - Nemunaitis, J. AU - Rizzo, J. AU - Hammond, L. A. AU - Takimoto, C. AU - Eckhardt, S. G. AU - Tolcher, A. AU - Britten, C. D. AU - Denis, L. AU - Ferrante, K. AU - Von Hoff, D. D. AU - Silberman, S. AU - Rowinsky, E. K. PY - 2001 DA - 2001// TI - Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies JO - J Clin Oncol VL - 19 ID - Hidalgo2001 ER - TY - STD TI - Erlotinib in Higher Risk Myelodysplastic Syndrome - NCT01085838.http://clinicaltrials.gov/ct2/show/NCT01085838, UR - http://clinicaltrials.gov/ct2/show/NCT01085838 ID - ref6 ER - TY - STD TI - Erlotinib in combination with cetuximab - NCT00895362.http://www.clinicaltrials.gov/ct2/show/NCT00895362, UR - http://www.clinicaltrials.gov/ct2/show/NCT00895362 ID - ref7 ER - TY - JOUR AU - Djulbegovic, B. PY - 2007 DA - 2007// TI - Articulating and responding to uncertainties in clinical research JO - J Med Philos VL - 32 UR - https://doi.org/10.1080/03605310701255719 DO - 10.1080/03605310701255719 ID - Djulbegovic2007 ER - TY - JOUR AU - Behera, M. AU - Kumar, A. AU - Soares, H. P. AU - Sokol, L. AU - Djulbegovic, B. PY - 2007 DA - 2007// TI - Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design JO - Cancer Control VL - 14 ID - Behera2007 ER - TY - BOOK AU - Piantadosi, S. PY - 2005 DA - 2005// TI - Clinical Trials: A Methodologic Perspective PB - Wiley Interscience CY - Hoboken, NJ UR - https://doi.org/10.1002/0471740136 DO - 10.1002/0471740136 ID - Piantadosi2005 ER - TY - JOUR AU - O’Quigley, J. PY - 2009 DA - 2009// TI - Commentary on ‘Designs for dose-escalation trials with quantitative responses’ JO - Stat Med VL - 28 UR - https://doi.org/10.1002/sim.3742 DO - 10.1002/sim.3742 ID - O’Quigley2009 ER - TY - JOUR AU - Lawitz, E. AU - Rodriguez-Torres, M. AU - Muir, A. J. AU - Kieffer, T. L. AU - McNair, L. AU - Khunvichai, A. AU - McHutchison, J. G. PY - 2008 DA - 2008// TI - Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients JO - J Hepatol VL - 49 UR - https://doi.org/10.1016/j.jhep.2008.03.027 DO - 10.1016/j.jhep.2008.03.027 ID - Lawitz2008 ER - TY - JOUR AU - Smith, L. S. AU - Nelson, M. AU - Naik, S. AU - Woten, J. PY - 2011 DA - 2011// TI - Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C JO - Ann Pharmacother VL - 45 UR - https://doi.org/10.1345/aph.1P430 DO - 10.1345/aph.1P430 ID - Smith2011 ER - TY - STD TI - Raziee H-R, Lemmens T: Personal communication. ID - ref14 ER - TY - JOUR AU - Chung, K. Y. AU - Shia, J. AU - Kemeny, N. E. AU - Shah, M. AU - Schwartz, G. K. AU - Tse, A. AU - Hamilton, A. AU - Pan, D. AU - Schrag, D. AU - Schwartz, L. AU - Klimstra, D. S. AU - Fridman, D. AU - Kelsen, D. P. AU - Saltz, L. B. PY - 2005 DA - 2005// TI - Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.08.037 DO - 10.1200/JCO.2005.08.037 ID - Chung2005 ER - TY - JOUR AU - Lane, E. L. AU - Bjorklund, A. AU - Dunnett, S. B. AU - Winkler, C. PY - 2010 DA - 2010// TI - Neural grafting in Parkinson’s disease unraveling the mechanisms underlying graft-induced dyskinesia JO - Prog Brain Res VL - 184 UR - https://doi.org/10.1016/S0079-6123(10)84015-4 DO - 10.1016/S0079-6123(10)84015-4 ID - Lane2010 ER - TY - JOUR AU - Holden, C. PY - 2009 DA - 2009// TI - Neuroscience. Fetal cells again? JO - Science VL - 326 UR - https://doi.org/10.1126/science.326_358 DO - 10.1126/science.326_358 ID - Holden2009 ER - TY - CHAP AU - Freeman, T. B. AU - Brundin, P. ED - Brundin, P. ED - Olanow, C. W. PY - 2006 DA - 2006// TI - Important Aspects of Surgical Methodology for Transplantation in Parkinson’s Disease BT - Restorative Therapies in Parkinson’s Disease PB - Springer Science + Business Media, LLC CY - New York ID - Freeman2006 ER - TY - JOUR AU - Stohl, W. AU - Hilbert, D. M. PY - 2012 DA - 2012// TI - The discovery and development of belimumab: the anti-BLyS-lupus connection JO - Nat Biotechnol VL - 30 UR - https://doi.org/10.1038/nbt.2076 DO - 10.1038/nbt.2076 ID - Stohl2012 ER - TY - JOUR AU - Booth, C. M. AU - Calvert, A. H. AU - Giaccone, G. AU - Lobbezoo, M. W. AU - Eisenhauer, E. A. AU - Seymour, L. K. PY - 2008 DA - 2008// TI - Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT) JO - Eur J Cancer VL - 44 UR - https://doi.org/10.1016/j.ejca.2007.07.031 DO - 10.1016/j.ejca.2007.07.031 ID - Booth2008 ER - TY - JOUR AU - Macaluso, M. AU - Krams, M. AU - Preskorn, S. H. PY - 2011 DA - 2011// TI - Phase I trials: from traditional to newer approaches part II JO - J Psychiatr Pract VL - 17 UR - https://doi.org/10.1097/01.pra.0000400265.37666.4e DO - 10.1097/01.pra.0000400265.37666.4e ID - Macaluso2011 ER - TY - JOUR AU - Anderson, J. A. AU - Kimmelman, J. PY - 2010 DA - 2010// TI - Extending clinical equipoise to phase 1 trials involving patients: unresolved problems JO - Kennedy Inst Ethics J VL - 20 UR - https://doi.org/10.1353/ken.0.0307 DO - 10.1353/ken.0.0307 ID - Anderson2010 ER - TY - JOUR AU - Bretzner, F. AU - Gilbert, F. AU - Baylis, F. AU - Brownstone, R. M. PY - 2011 DA - 2011// TI - Target populations for first-in-human embryonic stem cell research in spinal cord injury JO - Cell Stem Cell VL - 8 UR - https://doi.org/10.1016/j.stem.2011.04.012 DO - 10.1016/j.stem.2011.04.012 ID - Bretzner2011 ER - TY - JOUR AU - Solbakk, J. H. AU - Zoloth, L. PY - 2011 DA - 2011// TI - The tragedy of translation: the case of “first use” in human embryonic stem cell research JO - Cell Stem Cell VL - 8 UR - https://doi.org/10.1016/j.stem.2011.04.009 DO - 10.1016/j.stem.2011.04.009 ID - Solbakk2011 ER - TY - JOUR AU - Marks, W. J. AU - Ostrem, J. L. AU - Verhagen, L. AU - Starr, P. A. AU - Larson, P. S. AU - Bakay, R. A. AU - Taylor, R. AU - Cahn-Weiner, D. A. AU - Stoessl, A. J. AU - Olanow, C. W. AU - Bartus, R. T. PY - 2008 DA - 2008// TI - Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial JO - Lancet Neurol VL - 7 UR - https://doi.org/10.1016/S1474-4422(08)70065-6 DO - 10.1016/S1474-4422(08)70065-6 ID - Marks2008 ER - TY - JOUR AU - Roberts, T. G. AU - Goulart, B. H. AU - Squitieri, L. AU - Stallings, S. C. AU - Halpern, E. F. AU - Chabner, B. A. AU - Gazelle, G. S. AU - Finkelstein, S. N. AU - Clark, J. W. PY - 2004 DA - 2004// TI - Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials JO - JAMA VL - 292 UR - https://doi.org/10.1001/jama.292.17.2130 DO - 10.1001/jama.292.17.2130 ID - Roberts2004 ER - TY - JOUR AU - Kimmelman, J. AU - Duckworth, K. AU - Ramsay, T. AU - Voss, T. AU - Ravina, B. AU - Emborg, M. E. PY - 2011 DA - 2011// TI - Risk of surgical delivery to deep nuclei: a meta-analysis JO - Mov Disord VL - 26 UR - https://doi.org/10.1002/mds.23770 DO - 10.1002/mds.23770 ID - Kimmelman2011 ER -